GlassScriptPhysician profile
Sarah Crabtree
NPI 1124809348
$1,895.54
in general payments reported to CMS, 2019-2025
17 companies · $593 in 2025
The $593 reported for 2025 was more than what 79% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $460 · 2024: $843 · 2025: $593.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,896.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,895.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $443.95 | 2023-2025 | |
| Abiomed | $229.44 | 2023-2024 | Impella |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $227.23 | 2023-2025 | Lifevest |
| Inari Medical, INC. | $188.74 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Boston Scientific Corporation | $172.82 | 2023-2025 | Watchman Flx, General - Therapies, Lux-Dx Insertable Cardiac Monitor |
| Merck Sharp & Dohme LLC | $136.32 | 2024-2025 | Verquvo |
| Kiniksa Pharmaceuticals International, Plc | $77.17 | 2024 | Arcalyst |
| Amgen INC. | $66.19 | 2023-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $65.90 | 2024-2025 | Camzyos, Eliquis |
| Cvrx, INC. | $62.35 | 2025 | Barostim Neo System |
| Pfizer INC. | $44.41 | 2024-2025 | |
| Inspire Medical Systems, INC. | $44.04 | 2025 | Inspire |
| Astrazeneca Pharmaceuticals LP | $43.89 | 2023-2024 | Wainua |
| Abbott Laboratories | $34.58 | 2024 | Cardiomems |
| Penumbra, INC. | $26.55 | 2024 | Indigo System |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Elutia, INC. | $17.99 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.97 | 2024 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Crabtree listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.